Tobira Therapeutics Retains JFK Communications for Strategic Public Relations Support
Princeton-Based Biopharmaceutical Company Turns to JFK for its Expertise in Drug Development and Data Communications
Princeton, NJ, March 3, 2010 — JFK Communications, Inc. announced today the firm has added new client, Tobira Therapeutics, a private biopharmaceutical company focused on developing and commercializing innovative antiviral compounds to treat HIV disease to its growing client roster. JFK Communications will provide Tobira Therapeutics with strategic communications support for its drug development pipeline and clinical presence at the 2010 Conference on Retroviruses and Opportunistic Infections (CROI).
“Our extensive experience in virology and biopharmaceutical drug development makes us a strong communications partner to help Tobira navigate the complexities of communicating in the HIV treatment and patient advocacy arena,” said John Kouten, Chief Executive Officer, JFK communications, Inc.
As part of Tobira’s overall communications strategy, JFK Communications will be working closely with partner agency Sensei Health Communications of New York to provide the company with additional area-specific expertise in the HIV/infection disease space.
JFK Communications, Inc. provides innovative public relations solutions for the pharmaceutical, biotechnology and medical technology industries. For more information about JFK Communications’ capabilities or career opportunities, please visit the updated JFK website at www.jfkhealth.com, or call us at (609) 514-5117.